Found 1809 clinical trials
Customer Outcomes & Value Experiencing A New Monitoring Technology
To investigate whether novel insight features in new Blood Glucose Monitoring System (BGMs) can improve glycemic control.
- 0 views
- 19 Feb, 2024
Injections of Glutamic Acid Decarboxylase (GAD) for LADA Type of Diabetes
This study will evaluate the effects of 3 intra-nodal injections of GAD-alum (Diamyd), together with oral vitamin D supplementation. Safety and feasibility of the treatment will be evaluated and also effects on the immune system and on the preservation of endogenous insulin production.
- 0 views
- 19 Feb, 2024
Cardiometabolic Effects of Rapid Glucose Excursion
The effects of rapid glucose excursions, induced by intravenous bolus application of glucose in healthy probands, on cardiometabolic and inflammatory parameters will be investigated
- 0 views
- 19 Feb, 2024
At-Risk for Type 1 Diabetes Extension Study
This study is an extension of the NIH-sponsored AT-Risk (TN-10) type 1 diabetes study (NCT 01030861). Teplizumab-treated and placebo-treated participants in the NIH trial who develop clinical type 1 diabetes after the conclusion of that trial, are eligible to enroll and receive teplizumab treatment within one year of diagnosis of …
- 0 views
- 19 Feb, 2024
Internet Intervention for Diabetes Distress.
This study is designed to investigate the potential effectiveness of an internet-delivered intervention for diabetes distress in patients with type 2 diabetes.
- 0 views
- 20 Jun, 2025
- 19 locations
SGLT2 Inhibition in Older Obese Adults With Pre-diabetes
Inhibitors of the sodium-glucose co-transporter (SGLT2) are FDA-approved for the treatment of type 2 diabetes (T2DM). Their mechanism of action involves lowering of blood glucose concentration secondary to increased glucose excretion of glucose by the kidney.
- 0 views
- 19 Feb, 2024
Scripps Digital Diabetes: Cloud-Based Continuous Glucose Monitoring (CB CGM)
Individuals with diabetes in the hospital often experience poor glycemic control, which places them at greater risk for infection, neurological and cardiac complications, mortality, longer lengths of stay, readmissions, and higher healthcare costs.
- 0 views
- 19 Feb, 2024
Incidence of Diabetes and Metabolic Disorders After TIPS in Cirrhotic Patients
Based on our retrospective data, TIPS induces in 30% of cirrhotic patients metabolic disorders associated with diabetes or pre-diabetes. The main objective is to measure the cumulative incidence of diabetes and pre-diabetes 6 months after TIPS insertion.
- 0 views
- 19 Feb, 2024
UPENN Case Test Trial 2 (Do Not Make Any Changes)
UPENN Case Test Trial 2 (Do Not Make Any Changes)
- 0 views
- 02 May, 2025
- 1 location
UPENN Case Test Trial 4 (Do Not Make Any Changes)
UPENN Case Test Trial 4 (Do Not Make Any Changes)
- 0 views
- 02 May, 2025
- 1 location